APA

Fischl M. A., Burnside A. E., Farthing C. E., Thompson M. A., Bellos N. C., Williams V. C., Kauf T. L., Wannamaker P. G. & Shaefer M. S. (20040316). Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. : Pharmacotherapy.

Chicago

Fischl Margaret A, Burnside Alfred E, Farthing Charles E, Thompson Melanie A, Bellos Nicholaos C, Williams Vanessa C, Kauf Teresa L, Wannamaker Paul G and Shaefer Mark S. 20040316. Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. : Pharmacotherapy.

Harvard

Fischl M. A., Burnside A. E., Farthing C. E., Thompson M. A., Bellos N. C., Williams V. C., Kauf T. L., Wannamaker P. G. and Shaefer M. S. (20040316). Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. : Pharmacotherapy.

MLA

Fischl Margaret A, Burnside Alfred E, Farthing Charles E, Thompson Melanie A, Bellos Nicholaos C, Williams Vanessa C, Kauf Teresa L, Wannamaker Paul G and Shaefer Mark S. Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. : Pharmacotherapy. 20040316.